Endometriosis and malignancy: The intriguing relationship.
breast cancer
endometrial cancer
endometriosis
ovarian cancer
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
28
09
2020
received:
20
05
2020
accepted:
06
01
2021
pubmed:
9
1
2021
medline:
18
9
2021
entrez:
8
1
2021
Statut:
ppublish
Résumé
To determine the prevalence and study the association of ovarian, uterine, and breast cancers with endometriosis. A cross-sectional study of all women with a tissue-proven diagnosis of endometriosis postoperatively in a tertiary care hospital between January 1, 2010, and December 31, 2019, was conducted to determine the prevalence of coexistent malignancy. Patient details were obtained from electronic clinical records. Univariate analysis followed by multivariate analysis was done to find independent risk factors associated with malignancy. Out of 800 patients, 104 (13.0%) were found to have coexistent malignancy: ovarian (50, 6.2%); endometrial (33, 4.1%); synchronous ovarian and endometrial (7, 0.9%); and breast (14, 1.8%). Increasing age (odds ratio [OR] 1.13; 95% confidence interval [CI] 1.09-1.16), higher levels of cancer antigen 125 (CA 125) (OR 1.002; 95% CI 1.001-1.005), postmenopausal status (OR 6.2; 95% CI 2.0-19.2), duration of endometriosis over 5 years (OR 4.7; 95% CI 2.5-9.0), and endometriomas larger than 8 cm (area under the curve 0.83) were predictive of coexistent malignancy. Endometriosis is associated with an increased risk of ovarian, endometrial, and breast malignancy. Increasing age, postmenopausal status, higher levels of CA 125, larger endometrioma, and long-standing disease are predictive risk factors.
Substances chimiques
CA-125 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
72-78Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021 International Federation of Gynecology and Obstetrics.
Références
Nezhat F, Datta MS, Hanson V, Pejovic T, Nezhat C, Nezhat C. The relationship of endometriosis and ovarian malignancy: a review. Fertil Steril. 2008;90(5):1559-1570.
Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 1997;176(3):572-579.
Krawczyk N, Banys-Paluchowski M, Schmidt D, Ulrich U, Fehm T. Endometriosis-associated malignancy. Geburtshilfe Frauenheilkd. 2016;76(2):176-181.
Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261-275.
Mogensen JB, Kjaer SK, Mellemkjaer L, Jensen A. Endometriosis and risks for ovarian, endometrial and breast cancers: a nationwide cohort study. Gynecol Oncol. 2016;143(1):87-92.
Fukunaga M, Ushigome S. Epithelial metaplastic changes in ovarian endometriosis. Mod Pathol. 1998;11(8):784-788.
Kontoravdis A, Augoulea A, Lambrinoudaki I, et al. Ovarian endometriosis associated with ovarian cancer and endometrial-endocervical polyps. J Obstet Gynaecol Res. 2007;33(3):294-298.
Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol. 2001;20(2):133-139.
Heidemann LN, Hartwell D, Heidemann CH, Jochumsen KM. The relation between endometriosis and ovarian cancer-a review. Acta Obstet Gynecol Scand. 2014;93(1):20-31.
Zucchetto A, Serraino D, Polesel J, et al. Hormone related factors and gynecological conditions in relation to endometrial cancer risk. Eur J Cancer Prev. 2009;18(4):316-321.
Kok VC, Tsai HJ, Su CF, Lee CK. The risks for ovarian, endometrial, breast, colorectal, and other cancers in women with newly diagnosed endometriosis or adenomyosis: a population-based study. Int J Gynecol Cancer. 2015;25(6):968-976.
Melin A, Sparén P, Bergqvist A. The risk of cancer and the role of parity among women with endometriosis. Hum Reprod. 2007;22(11):3021-3026.
Chuang SC, Wu GJ, Lu YS, Lin CH, Hsiung CA. Associations between medical conditions and breast cancer risk in Asians: A Nationwide Population-Based Study in Taiwan. PLoS One. 2015;10(11):e0143410.
Kalaitzopoulos DR, Mitsopoulou A, Iliopoulou SM, Daniilidis A, Samartzis EP, Economopoulos KP. Association between endometriosis and gynecological cancers: a critical review of the literature. Arch Gynecol Obstet. 2020;301(2):355-367.
Kim HS, Kim TH, Chung HH, Song YS. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer. 2014;110(7):1878-1890.
Bassiouny D, El-Baz MA, Gamil TM, et al. Endometriosis-associated ovarian cancer is a subset with a more favorable outcome and distinct clinical-pathologic characteristics. Int J Gynecol Pathol. 2019;38(5):435-442.
Kobayashi H, Sumimoto K, Kitanaka T, et al. Ovarian endometrioma-risks factors of ovarian cancer development. Eur J Obstet Gynecol Reprod Biol. 2008;138(2):187-193.
Yu HC, Lin CY, Chang WC, et al. Increased association between endometriosis and endometrial cancer: a nationwide population-based retrospective cohort study. Int J Gynecol Cancer. 2015;25(3):447-452.
Taniguchi F. New knowledge and insights about the malignant transformation of endometriosis. J Obstet Gynaecol Res. 2017;43(7):1093-1100.
Vercellini P, Viganò P, Buggio L, et al. Perimenopausal management of ovarian endometriosis and associated cancer risk: when is medical or surgical treatment indicated? Best Pract Res Clin Obstet Gynaecol. 2018;51:151-168.
Noli S, Cipriani S, Scarfone G, et al. Long term survival of ovarian endometriosis associated clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer. 2013;23(2):244-248.
Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100(8):1315-1319.
Roncolato F, Lindermann K, Willson ML, Martyn J, Mileshkin L. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2019;10(10):CD012160.
Herreros-Villanueva M, Chen CC, Tsai EM, Er TK. Endometriosis-associated ovarian cancer: What have we learned so far? Clin Chim Acta. 2019;493:63-72.